Generic name: erdafitinib
Used for: Advanced urothelial (bladder) cancer with an FGFR3 change
Ask for the cash price
Balversa
We didn’t find one.
Free from the maker, if you qualify Johnson & Johnson Patient Assistance Program. Patients’ income must be equal to or less than 300% of Federal Poverty Level (FPL).
Or call 1-833-742-0791.
Details for each option
Savings card from Johnson & Johnson
Or call 1-833-742-0791.
“Eligible patients pay $5 per fill.”
From the maker’s offer on jnjwithme.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.
There isn’t one. An authorized generic is Balversa itself, from the same company, sold without the brand name, and usually for less. For now Balversa is the only choice; its maker’s savings card can lower what you pay.
We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.
BALVERSA is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy.
Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA.
Limitations of Use
BALVERSA is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.
Source: the FDA label for Balversa (Janssen Products LP), October 24, 2025. Full label on DailyMed
Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/balversa/